Skip to main content Skip to navigation
BUV496 Rat Anti-Mouse CD123
Product Details
Down Arrow Up Arrow

BD OptiBuild™
Il3ra; IL-3RA; IL-3R-alpha; IL-3 Receptor alpha; IL-3 Receptor α; SUT-1
Mouse (Tested in Development)
Rat IgG2a, κ
Mouse IL-3R transfected CTLL cells
Flow cytometry (Qualified)
0.2 mg/ml
Aqueous buffered solution containing ≤0.09% sodium azide.

Preparation And Storage

Store undiluted at 4°C and protected from prolonged exposure to light. Do not freeze. The monoclonal antibody was purified from tissue culture supernatant or ascites by affinity chromatography. The antibody was conjugated with BD Horizon BUV496 under optimal conditions that minimize unconjugated dye and antibody.

Recommended Assay Procedures

For optimal and reproducible results, BD Horizon Brilliant Stain Buffer should be used anytime two or more BD Horizon Brilliant dyes (including BD OptiBuild Brilliant reagents) are used in the same experiment.  Fluorescent dye interactions may cause staining artifacts which may affect data interpretation.  The BD Horizon Brilliant Stain Buffer was designed to minimize these interactions.  More information can be found in the Technical Data Sheet of the BD Horizon Brilliant Stain Buffer (Cat. No. 563794).

Product Notices

  1. This antibody was developed for use in flow cytometry.
  2. The production process underwent stringent testing and validation to assure that it generates a high-quality conjugate with consistent performance and specific binding activity. However, verification testing has not been performed on all conjugate lots.
  3. Researchers should determine the optimal concentration of this reagent for their individual applications.
  4. An isotype control should be used at the same concentration as the antibody of interest.
  5. Caution: Sodium azide yields highly toxic hydrazoic acid under acidic conditions. Dilute azide compounds in running water before discarding to avoid accumulation of potentially explosive deposits in plumbing.
  6. For fluorochrome spectra and suitable instrument settings, please refer to our Multicolor Flow Cytometry web page at
  7. Please refer to for technical protocols.
  8. BD Horizon Brilliant Stain Buffer is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,575,303; 8,354,239.
  9. BD Horizon Brilliant Ultraviolet 496 is covered by one or more of the following US patents: 8,110,673; 8,158,444; 8,227,187; 8,575,303; 8,354,239.
750813 Rev. 4
Antibody Details
Down Arrow Up Arrow

The 5B11 monoclonal antibody specifically recognizes mouse CD123, the α chain subunit (IL-3Rα) of the mouse IL-3 receptor. The IL-3Rα chain is a 60-70 kD transmembrane glycoprotein that binds IL-3 with low affinity but cannot transduce signals by itself.  The  mouse IL-3Rα chain can complex with either of two homologous β chain subunits (βc and βIL-3) to form high-affinity heterodimeric IL-3 receptors.  The βc chain is the common β chain subunit that can complex with the α subunits of the mouse IL-3R, IL-5R and GM-CSFR to form high-affinity receptors. The βIL-3 subunit can form high affinity IL-3 receptor complexes with only the IL-3Rα subunit. The βIL-3 subunit clone is specific for mouse IL-3 and binds with low affinity. The immunogen used to generate the 5B11 hybridoma was CTLL cells transfected with the mouse IL-3R alpha chain. The 5B11 antibody does not block the binding of IL-3 protein to the high affinity IL-3 receptor heterodimer.

The antibody was conjugated to BD Horizon™ BUV496 which is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This dye is a tandem fluorochrome of BD Horizon BUV395 with an Ex Max of 348-nm and an acceptor dye with an Em Max at 496-nm. BD Horizon BUV496 can be excited by the ultraviolet laser (355 nm) and detected with a 515/30 nm filter with a 450LP. Due to the excitation of the acceptor dye by other laser lines, there may be significant spillover into the channel detecting BD Horizon V500 or BV510 (eg, 525/40-nm filter). However, the spillover can be corrected through compensation as with any other dye combination.

750813 Rev. 4
Format Details
Down Arrow Up Arrow
The BD Horizon Brilliant™ Ultraviolet 496 (BUV496) Dye is part of the BD Horizon Brilliant™ Ultraviolet family of dyes. This tandem fluorochrome is comprised of a BUV395 donor with an excitation maximum (Ex Max) of 350-nm and an acceptor dye with an emission maximum (Em Max) at 496-nm. BUV496, driven by BD innovation, is designed to be excited by the ultraviolet laser (355-nm) and detected using an optical filter centered near 500-nm (e.g., 515/30-nm bandpass filter). The acceptor dye can be excited by the Violet (405-nm) laser resulting in cross-laser excitation and fluorescence spillover. Please ensure that your instrument’s configurations (lasers and optical filters) are appropriate for this dye.
Ultraviolet 355 nm
350 nm
496 nm
750813 Rev.4
Citations & References
Down Arrow Up Arrow

Development References (3)

  1. Hara T, Miyajima A. Two distinct functional high affinity receptors for mouse interleukin-3 (IL-3). EMBO J. 1992; 11(5):1875-1884. (Biology). View Reference
  2. Ichihara M, Hara T, Takagi M, Cho LC, Gorman DM, Miyajima A. Impaired interleukin-3 (IL-3) response of the A/J mouse is caused by a branch point deletion in the IL-3 receptor alpha subunit gene. EMBO J. 1995; 14(5):939-950. (Clone-specific: Flow cytometry). View Reference
  3. Mueller DL, Chen ZM, Schwartz RH, Gorman DM, Kennedy MK. Subset of CD4+ T cell clones expressing IL-3 receptor alpha-chains uses IL-3 as a cofactor in autocrine growth. J Immunol. 1994; 153(7):3014-3027. (Clone-specific: Flow cytometry). View Reference
750813 Rev. 4

Please refer to Support Documents for Quality Certificates

Global - Refer to manufacturer's instructions for use and related User Manuals and Technical data sheets before using this products as described

Comparisons, where applicable, are made against older BD Technology, manual methods or are general performance claims.  Comparisons are not made against non-BD technologies, unless otherwise noted.

For Research Use Only. Not for use in diagnostic or therapeutic procedures.